A $75 Copay Cliff for GLP-1 Adherence as New Mexico's Medicaid Ozempic Bill Climbs
Friday, October 2, 2026 · 10 min
A JAMA Health Forum study finds GLP-1 nonadherence tops 80% once monthly out-of-pocket costs pass $75, while New Mexico's Medicaid Ozempic spending hit $38.7 million in 2025. Plus survodutide's Phase 3 in NEJM, the amylin tolerability tradeoff, and Novo's injection-to-pill switch data.
Listen
Show notes
A JAMA Health Forum study finds GLP-1 nonadherence tops 80% once monthly out-of-pocket costs pass $75, while New Mexico's Medicaid Ozempic spending hit $38.7 million in 2025. Plus survodutide's Phase 3 in NEJM, the amylin tolerability tradeoff, and Novo's injection-to-pill switch data.
In this episode
- Higher GLP-1 costs lead to lower adherence | EurekAlert! — EurekAlert!
Higher GLP-1 costs lead to lower adherence | EurekAlert! News Release 30-Sep-2026 # Higher GLP-1 costs lead to lower adherence Patients significantly less likely to use the weight loss medication when monthly costs exceed $75 University of Georgia Semaglutides, or GLP-1s, can produce substantial weight loss if individuals adhere to their doctor’s instructions. But a new study from the…
- Ozempic driving massive increase in New Mexico Medicaid prescription drug spending | Local News | santafenewmexican.com — Margaret O'Hara mohara@sfnewmexican.com
Ozempic driving massive increase in New Mexico Medicaid prescription drug spending | Local News | santafenewmexican.com # Ozempic driving massive increase in New Mexico Medicaid prescription drug spending Follow Margaret O'Hara - By Margaret O'Hara mohara@sfnewmexican.com #### Margaret O'Hara Health Care Accountability Reporter - Author email (mohara@sfnewmexican.com) - Sep 29, 2026…
- Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes - BioSpace — BioSpace
Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes - BioSpace # Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic…
- Novel amylin drug confers 10% weight loss, well tolerated — Dorothy Brooks
# Novel amylin drug confers 10% weight loss, well tolerated Author: Erik Swain Published: 2026-09-30T00:00:00 Source: healio.com (healio.com) Language: en ## Story Novel amylin drug confers 10% weight loss, well tolerated By Erik Swain Fact checked by Richard Smith # Novel amylin drug confers 10% weight loss with adverse events comparable to placebo September 30, 2026 5 min read By…
- People switching from weight-loss injections to Novo's Wegovy® pill lost 4.1% body weight on average after three months, according to real-world data presented at EASD2026 — Annika Kim Constantino
# People switching from weight-loss injections to Novo's Wegovy® pill lost 4.1% body weight on average after three months, according to real-world data presented at EASD2026 Author: NOVO NORDISK INC. Published: 2026-09-30T09:45:00+00:00 Source: prnewswire.com (prnewswire.com) Language: en ## Story People switching from weight-loss injections to Novo's Wegovy® pill lost 4.1% body weight on…